NR4A1 and breast cancer: In postmenopausal women who used AIs to treat early stage hormone receptor-positive BC, we found evidence that longer duration of AI use assessed at 6 years after BC diagnosis was associated with lower risk of stroke, all-cause mortality, CVD-related mortality, and non-CVD-related mortality.